Best Life Sciences Companies in Boulder, United States
The 81 best Life Sciences companies in Boulder, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Somalogic.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Boulder
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Somalogic Developer of protein-based assays for life science research | $664M | 66 mo ago | 319 | Larry Gold CEO | 796 patents Aptamer-based multiplexed protein/biomarker detection and quantitative proteomics assays. | — |
| 2 | Enveda 🦄 AI-based platform to decipher the chemistry of nature and develop new medicines 72Funding top 12%Moat top 32%Growth top 35%Market top 44% All 8 signals ▾Fundingtop 12% Moattop 32% Growthtop 35% Markettop 44% AItop 45% Talentbottom 49% Globalbottom 48% Techbottom 46% Funding: Raised $505M across 9 rounds · 9 rounds over 7 yrs (1.3/yr) Moat: Unicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 72/100 | $505M | 9 mo ago | — | Viswa Colluru Founder & CEO | — | — |
| 3 | Enveda Developer of an AI-enabled drug discovery platform to treat fibrosis or neurodegenerative disease | $224M | 24 mo ago | 175 | Viswa Colluru Founder & CEO | — | 2 job openings |
| 4 | Biodesix Developer of diagnostics assays for the detection of cancer | $200M | 43 mo ago | 217 217 → 360 (+66%) | — | 226 patents Molecular diagnostic tests for cancer, infectious diseases, and prognostic biomarkers using proteomics and AI | — |
| 5 | ArcherDX Developer of molecular cancer diagnostic products | $153M | 78 mo ago | 429 | John Iafrate Co-Founder | 107 patents Patents concentrated in chemistry & materials | — |
| 6 | Edgewise Therapeutics Developer of therapeutics for skeletal and cardiac muscle diseases | $145M | 66 mo ago | 33 | Alan Russell Co-Founder & Chief Scientific Officer | — | — |
| 7 | Enliven Therapeutics Developer of drugs for solid tumours and blood cancers | $140M | 27 mo ago | 27 | Anish Patel Co-Founder | — | — |
| 8 | NeuroMark Genomics Developer of a system for chronic rhinitis treatment via radiofrequency. | $110M | 4 mo ago | — | David Townley Co-Founder & CTO | — | — |
| 9 | Integrated Diagnostics Blood-based diagnostics for oncology. | $83M | 114 mo ago | 17 | — | 67 patents Molecular diagnostic assays for lung cancer and neurodegenerative disease biomarkers | — |
| 10 | OPX Biotechnologies Renewable converstion to biofuel | $60M | 179 mo ago | 61 | — | 120 patents Microbial biosynthesis of platform chemicals like 3‑hydroxypropionic acid and 1,4‑butanediol | — |
| 11 | VitriVax Developer of thermostable vaccines 37Funding top 23%Moat top 37%Patents top 42%Innovation top 48% All 6 signals ▾Fundingtop 23% Moattop 37% Patentstop 42% Innovationtop 48% Marketbottom 36% Globalbottom 36% Funding: Raised $55.5M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 7 patents rank vs industry peers · Fliar Intelligence Index 37/100 | $56M | 8 mo ago | 24 | — | 7 patents Stabilizing dried nucleic acid formulations and advanced CVD/ALD equipment for coating quality control | 1 job opening |
| 12 | Watchmaker Genomics Developer of gene-editing technology | $48M | 48 mo ago | 121 | Brian Kudlow Co-Founder | 36 patents Patents concentrated in chemistry & materials | 2 launchs |
| 13 | MiRagen Developer of microRNA-based therapeutic solutions for treating multiple diseases | $44M | 67 mo ago | 92 | Sanjoy Mahanty Co-Founder | — | — |
| 14 | GoodBelly Brand of nutrition drinks & supplements | $36M | 96 mo ago | 15 15 → 15 (+0%) | Juan-Carlos Gluth CEO | — | 1 launch |
| 15 | Viridian Therapeutics Developer of medicines for patients with serious and rare diseases | $34M | 1 mo ago | 94 | — | — | — |
| 16 | EndoShape Developing minimally invasive medical devices using radiopaque shape-memory biocompatible polymers | $29M | 111 mo ago | 13 | Stephen Hanlon CEO & President | 115 patents Fiber-based occlusive implants and radiopaque polymer medical devices for embolization | — |
| 17 | Think Bioscience Provider of synthetic biology platform to develop small-molecule therapeutics 22Funding top 30%Talent top 38%Moat top 39%Global bottom 39% All 6 signals ▾Fundingtop 30% Talenttop 38% Moattop 39% Globalbottom 39% Techbottom 30% Marketbottom 28% Funding: Raised $26.0M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 22/100 | $26M | 5 mo ago | 21 21 → 31 (+48%) | Jerome Fox Co-Founder & CEO | — | — |
| 18 | Arpeggio Provider of drug discovery platform for the treatment of cancer 24Funding top 27%Moat top 31%Talent top 38%Global bottom 37% All 6 signals ▾Fundingtop 27% Moattop 31% Talenttop 38% Globalbottom 37% Marketbottom 25% Newsbottom 22% Funding: Raised $25.4M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $25M | 7 mo ago | 8 | Laura Norris Co-Founder | — | — |
| 19 | Accure Acne Developer of Laser system device for acne treatment | $25M | 40 mo ago | 6 | Christopher Carlton Chairman of the Board | 60 patents Photothermal acne therapy devices with integrated temperature sensing and closed-loop dosimetry control | — |
| 20 | Clovis Oncology Developer of immunotherapy drugs for the treatment of cancer | $20M | 66 mo ago | 280 | — | 49 patents Combination cancer immunotherapy with anti‑angiogenic agents and high‑dose PARP inhibitor formulations. | — |
| 21 | Rebalance Health Provider of nutritional supplements based on the questionnaire | $19M | 33 mo ago | 18 | — | — | — |
| 22 | InDevR Manufacturer of biotherapeutics, vaccines and diagnostic products | $16M | 41 mo ago | 42 | Laura Kuck Co-Founder & EVP | 52 patents Molecular diagnostics platforms for nucleic acid and protein assay multiplexing | — |
| 23 | Ambrosia Biosciences Developer of small molecule-based therapies for metabolic disorders | $16M | 2 mo ago | — | Nick Traggis Founder & CEO | — | — |
| 24 | Green Chef Provider of organic meal kit based on subscription | $16M | 134 mo ago | 300 | — | — | — |
| 25 | Mosaic Biosciences Protein and antibody therapeutics discovery from concept to clinical candidate | $15M | 48 mo ago | 36 | — | — | — |
| 26 | Proov Developer of progesterone based fertility test kits | $10M | 59 mo ago | 22 | Amy Beckley Founder & CEO | — | — |
| 27 | Sinopsys Surgical Lacrimal stent and procedure to treat sinusitis | $10M | 135 mo ago | 1 | Harry Ross CEO & President | 82 patents Paranasal sinus fluid access implants and delivery tools for sinus treatment | — |
| 28 | CrossTrees Medical Fabric pod to control flow of bone cement in surgeries for spinal compression fractures | $9M | 200 mo ago | — | Bob Scribner Director | — | — |
| 29 | Sophie Culverhouse Global healthcare technology company providing innovative medical devices and therapies | $9M | 146 mo ago | 25 | — | — | — |
| 30 | Good Day Chocolate Doctor-founded chocolate supplements delivering relief and wellness with fair trade ingredients | $7M | 74 mo ago | 4 | — | — | — |
| 31 | Crestone Pharma Manufacturer of small molecule drugs for infectious diseases | $7M | 16 mo ago | 8 | — | — | — |
| 32 | Nice Recovery Systems Developer of a cold compression therapy device | $6M | 21 mo ago | 10 | Michael Ross Founder | — | 1 launch |
| 33 | Orbit Genomics Developer of cancer diagnostics and companion diagnostics for drugs in development | $4M | 14 mo ago | 6 | Dede Willis Co-Founder & CEO | 15 patents Microsatellite genotyping and sample classification tools for genomic analysis | — |
| 34 | Prohibix Developer of next-generation injectable hyaluronic acid products | $3M | 57 mo ago | — | Brendan Purcell Co-Founder and CEO | 8 patents Injectable hyaluronic‑acid based dermal fillers and collagen‑stimulating hydrogels. | — |
| 35 | Fitbionic Prosthetic foot | $2M | 154 mo ago | — | Jerome Rifkin Founder & ex-CEO | — | — |
| 36 | Cime Therapeutics A biotechnology company focused on advancing drug discovery through a chemistry-first platform | $2M | 14 mo ago | — | James Brewster Co-Founder & CEO | — | — |
| 37 | Sachi Bioworks Developer of an integrative bioinformatics platform for drug discovery using AI | $2M | 15 mo ago | 5 | Anushree Chatterjee Co-Founder & CEO | — | 1 launch |
| 38 | Source MDx Molecular diagnostic solutions for early detection of cancer | $2M | 196 mo ago | — | — | 19 patents Cross-species gene expression panels for diagnosing and monitoring autoimmune diseases | — |
| 39 | Althea Developer of research tools to manage the psychedelic drugs into healthcare settings | $2M | 22 mo ago | — | Niko Skievaski Co-Founder & CEO | 64 patents Protein crystal engineering for therapeutic proteins and industrial enzymes | — |
| 40 | iSplack Manufacturer of athlete-focused, science-backed body care products | $1M | 76 mo ago | 5 | Jean OBrien Co-Founder & CEO | — | — |
| 41 | Nanoly Bioscience Develops technology to eliminate refrigeration for vaccines and protein therapeutics | $1M | 121 mo ago | 4 | Balaji Sridhar Co-Founder & CEO | — | — |
| 42 | Aspero Medical Developer of gastrointestinal balloon endoscopy | $1M | 23 mo ago | 3 | — | — | — |
| 43 | Respirogen Developer of oxygen delivery technology | $750K | 84 mo ago | 4 | Bob Scribner CEO | 11 patents Oxygen delivery systems for medical, cosmetic, and food applications, plus gas‑sensitive packaging. | — |
| 44 | GeoPalz Activity trackers for children | $120K | 159 mo ago | 3 | Alexandra Zan O'Leary Co-Founder & COO | — | — |
Top 12 Life Sciences companies in Boulder
#1
Enveda 🦄Series D · Boulder, Colorado · founded 2019$504.8Mraised▾
AI-based platform to decipher the chemistry of nature and develop new medicines. It employs advanced computational methods, high throughput automation, and metabolomics to identify potential treatments for various diseases. It leverages chemical knowledge of nature to accelerate drug discovery and development.
- Sep 2025Series D$150M
- Feb 2025Series C—
- Nov 2024Series C$130M
- Jun 2024Series B$55M
#2
Series C · Boulder, Colorado · founded 2018$110.2Mraised▾
Developer of a system for chronic rhinitis treatment via radiofrequency. The system uses low-power energy to disrupt posterior nasal nerves. It is designed as a minimally invasive solution. The technology includes a flexible shaft and leaflets for precise treatment.
- Feb 2026Series C$74.3M
- Dec 2024Series B—
- Jan 2021Series B$25M
- Jul 2020Grant (prize money)—
#3
Public · Boulder, Colorado · founded 2007 · 94 employees$34.5Mraised▾
Developer of medicines for patients with serious and rare diseases. The company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
- May 2026Post IPO$20M
- Feb 2015Series A$8.5M
- Sep 2010Series A$6M
#4
Series B · Boulder, Colorado · founded 2024$16Mraised▾
Developer of small molecule-based therapies for metabolic disorders. It offers an enzyme technology platform that converts obesity-promoting sugars into minimal-calorie rare sugars to treat obesity.
- Mar 2026Series B$100M
- Jul 2024Series A$16M
#5
Series A · Boulder, Colorado · founded 2019 · 21 employees$26Mraised▾
Provider of synthetic biology platform to develop small-molecule therapeutics. The company's platform combines applied microbiology, enzymology, and data science to develop medicines against difficult-to-drug proteins.
- Jan 2026Series A$55M
- May 2024Seed$6M
- Aug 2022Seed$17M
- Dec 2020Grant (prize money)$255.9K
#6
Series B · Boulder, Colorado · founded 2014 · 24 employees$55.5Mraised▾
Developer of thermostable vaccines and vaccine formulations. It is using a proprietary platform technology named a single shot, prime + boost microparticle vaccine platform and developed at the University of Colorado. The platform uses nanoparticles of antigen and adjuvant in an amorphous disaccharide glass matrix, which improves the stability and solubility of the product. The company is using the platform to develop thermostable vaccines of Anthrax, Botulinum toxin, Ebola glycoprotein, and HPV16 L1 capsomere.
- Oct 2025Series B$17.2M
- Jun 2025Series B$29.4M
- Apr 2025Grant (prize money)$5M
- Dec 2024Grant (prize money)$3.6M
#7
Series B · Boulder, Colorado · founded 2017 · 8 employees$25.4Mraised▾
Provider of drug discovery platform for the treatment of cancer. The company uses DNA sequencing and CRISPR-based screening technology to identify therapeutic targets and biomarkers to treat cancer. The company is developing drug candidates for Sarcomas, Lung Adenocarcinoma, and autoimmune diseases.
- Nov 2025Series B$20M
- Mar 2025Series A$4M
- Aug 2022Series A$20.2M
- Jan 2020Seed$3.2M
#8
Series B · Boulder, Colorado · founded 2019 · 175 employees$224.5Mraised▾
Developer of a drug discovery platform designed to capitalize on the chemical diversity and evolutionary significance of nature's hidden chemistry to create high-value small-molecule medicines. The company's platform technology combines machine learning, metabolomics, and robotics to analyze a natural sample for both chemical structure and biological activity and function, eliminating the need for isolating individual compounds or conducting extensive experimentation, they have a sizeable computable ethnobotany dataset to focus on the most medicinally significant plants and have a growing portfolio of early-stage assets in areas of unmet medical need, it has effectivelymore
#9
Funding Raised · Boulder, Colorado · founded 2015 · 8 employees$6.6Mraised▾
Manufacturer of small molecule drugs for infectious diseases. The lead candidate CRS3123 is a narrow-spectrum protein synthesis inhibitor for Clostridium difficile infections. The other lead candidates Oral Gram-positive and NTM/TB include a DNA polymerase inhibitor for Gram-Positive bacteria (MRSA, Streptococcus, etc.), and Tuberculosis.
- Feb 2025Grant (prize money)$288.1K
- Aug 2023Grant (prize money)$295.8K
- May 2020Grant (prize money)$250K
- Apr 2020Grant (prize money)$143.9K
#10
Public · Boulder, Colorado · founded 2019 · 27 employees$140Mraised▾
Developer of drugs for solid tumors and blood cancers. It offers precision oncology therapeutics which include ELVN-001, a small molecule kinase inhibitor that target the BCR-ABL gene fusion, andELVN-002 a HER2 inhibitor with activity against various HER2 mutations for non-small cell lung cancer and solid tumors.
- Mar 2024Post IPO$90M
- Feb 2023Post IPO$165M
- Dec 2020Post IPO$85M
- 2020Post IPO—
#11
Seed · Boulder, Colorado · founded 2016 · 6 employees$4Mraised▾
Developer of cancer diagnostics and companion diagnostics for drugs in development. The company has developed technologies to accurately measure microsatellite variations and associate those variations with diseases, creating new diagnostic tools to evaluate the risk of certain cancers and for actionable clinical decision support. The company is currently developing a liquid biopsy test for the early detection of lung cancer and is also in the process of developing companion diagnostics.
- Apr 2025Grant (prize money)$2M
- Sep 2024Grant (prize money)$999.6K
- Jul 2024Seed$780K
- May 2021Grant (prize money)$250K
#12
Acquired · Boulder, Colorado · founded 1999 · 319 employees$664Mraised▾
Developer of protein-based assays for life science research. Its proprietary SOMAmer protein-binding reagents are a class of protein-binding molecules that behave both like aptamers and antibodies, while the SOMAscan assay enables the broad measurement of multiple proteins. The company offers its platform technology as reagents and kits for researchers. However, the company plans to develop LDT tests from a CLIA certified lab, as well as develop therapeutics based on SOMAmer.
- Dec 2020Series E$212M
- Nov 2020Series E$121M
- Oct 2020Grant (prize money)$1M
- Jul 2018Series E$200M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Boulder researches in biotechnology
- University of Colorado Boulder17
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.